"Ryzyko ciężkich powikłań po szczepieniach mRNA na COVID przewyższa stopień ochrony przed hospitalizacją na COVID"
Jednym z autorów artykułu pod w.w. tytułem, opublikowanego w "Vaccine", jest Peter Doshi jeden z redaktorów The British Medical Journal. Czapki z głów dla odwagi Dosha.
Ryzyko ciężkiego powikłania po szczepionce Moderny to 15.1 na 10 000 dawek, a 10 000 dawek ochrania przed hospitalizacją z powodu COVID 4 osoby. Dla Pfizera te liczby to 10.1 vs. 2.3
In the Moderna trial, the excess risk of serious AESIs (15.1 per 10,000 participants) was higher than the risk reduction for COVID-19 hospitalization relative to the placebo group (6.4 per 10,000 participants).
In the Pfizer trial, the excess risk of serious AESIs (10.1 per 10,000) was higher than the risk reduction for COVID-19 hospitalization relative to the placebo group (2.3 per 10,000 participants).
link do artykułu
https://www.sciencedirect.com/science/article/pii/S0264410X22010283
Other key findings from the paper:
There was a 16% higher risk of serious adverse events in mRNA vaccine recipients than in placebo recipients
There was a 43% higher risk of serious adverse events of special interest in mRNA vaccine recipients
mRNA vaccines are associated with more harm than initially estimated at the time of emergency authorization.
Authors call for a formal risk-benefit analysis of the mRNA vaccines to take place
The authors suggest that we’ll need trial participant data in order to complete this task
Authors encourage third-party replication of their study, with access to complete SAE case narratives.
The risks may be substantially less in some groups compared to others. Thus, knowing the actual demographics of those who experienced an increase in serious AESI in the vaccine group is necessary for a proper harm-benefit analysis
Artykuł omówiony w: